Neuromuscular

Here's some of what is coming soon to NeurologyLive® this week.

Barry J Byrne, MD, PhD, the chief medical advisor of MDA, also spoke about what he personally is most looking forward to at this year's meeting.

Global site reactivation for the MAGNITUDE-2 trial of nexiguran ziclumeran in hereditary transthyretin amyloidosis with polyneuropathy is underway, with enrollment completion expected in the second half of 2026.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 27, 2026.

In honor of Black History Month, neurologist Na Tosha Gatson, MD, PhD, reflects on structural inequities in neuro-oncology and advancing equity through mentorship, trial design, and institutional policy.

Neuro-oncology experts discussed how to differentiate classic PNS from immune-related neurologic adverse events, including the impact of prior immunotherapy exposure and the challenge of balancing neurologic stabilization with ongoing cancer treatment. [WATCH TIME: 5 minutes]

Phase 3 data showed efgartigimod improved ocular myasthenia symptoms, paving way for FDA filing and potential first targeted option for patients.

Grip strength offers neurologists a responsive, objective measure that captures treatment effects and real-world fluctuations—complementing disability scales and helping to guide decision-making in clinical practice.

MARINA trial shows del-desiran siRNA reaches muscle, lowers toxic DMPK RNA in DM1, with early functional gains.

EryDex failed to significantly improve neurologic outcomes compared with placebo in pediatric patients with ataxia-telangiectasia in the phase 3 NEAT trial.

Neuro-oncology experts outlined screening strategies, antibody testing, and patient factors that help distinguish paraneoplastic neurologic syndromes from treatment toxicity and immune-related events. [WATCH TIME: 6 minutes]

A duo of neuro-oncologists from Northwestern Medicine discussed how paraneoplastic neurologic syndromes differ from other cancer-related neurologic complications, highlighting key diagnostic challenges.

Early ALS trial showed that microbiome gut-brain therapy PLL001 is safe, paving way for 6-month phase 2 study testing efficacy and gut repair.

Two-year phase 3 data show Elevidys gene therapy slows Duchenne decline in boys, improving NSAA and walk tests with manageable safety.

A duo of neuro-oncologists from Northwestern Medicine explained how to distinguish paraneoplastic neurologic syndromes from treatment toxicity and metastatic disease. [WATCH TIME: 8 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

PTC Therapeutics pulls ataluren’s US NDA for nonsense-mutation Duchenne after FDA doubts efficacy, despite trial and registry signals of benefit.

Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms needed to advance brain health equity in 2026 and beyond.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jeff Chamberlain, PhD. [LISTEN TIME: 23 minutes]

The FDA granted premarket approval to Balt Inc.’s Squid liquid embolic agent for middle meningeal artery embolization, offering a minimally invasive option to reduce treatment failure in patients with large symptomatic chronic subdural hematomas.

The chief medical advisor at the Muscular Dystrophy Association also discussed what he personally is looking forward to at the conference this year. [WATCH TIME: 4 minutes]

52-week trial data shows inebilizumab sustains gains in generalized myasthenia gravis, cuts prednisone, and spotlights CD

Neurology experts highlighted ongoing developments in artificial intelligence applications, disease-modifying mechanisms, and genetic therapies expected to undergo evaluation. [WATCH TIME: 9 minutes]

Here's some of what is coming soon to NeurologyLive® this week.